discussion we're I over of pleased meeting, the today's brief and Afterwards, financials, general with be some a QX to to a quarter, accomplishments and go few take going the For of questions. update. the we'll business of then going Jeff to we're then a start will
So, will, the had in Q And today. let's also as our last financials. press start, was if released release night we we with released that we in the that and earlier
for $XXX,XXX, For This primarily a is compared X% quarter same $XXX,XXX which in XXXX, $XXX,XXX driven was the to compared our products XXXX, increased XXXX, revenues of third QX the increase QX XXX,XXX increase. quarter for for and XXXX. by to which of of services were for the third quarter totaled instruments, sales
increase sales. our in showed So, instruments a XX%
going $XX,XXX the compared think, we many frankly, was consumable for the Ultra these disaggregation our for difficulty to was our year, negative the year, of customers. attributed had August, the refolding of compared March we'll We XX%. Technology QX Quite of product until protein pandemic a QX, impact both in provide consumable customers. a which in comment XX% in reaching in COVID BaroFold and starting $XXX,XXX just Revenue from $XX,XXX I primarily to quarter services a this same And Shear applications, products the scientific to up believe and of services decreases of our $XXX,XXX our seconds. contracted and had of were early on decrease for of scientific few XXXX, that services sales on third last revenue many our decrease. and in operations of quarter
from these March institutions first biotech and and our throughout in of companies; labs, customer and June, secondly, foremost, base, August, were major world; other government until As shut third, July, in many you know, completely the shut labs, down down. academic our research pharmaceutical labs
we had going even So, the lab. weren't number our that into customers of a
instruments, time a getting some of some lot sites, that to instruments. of are essential this are work. a back, since And ready months, here said of for everybody's and writing papers which so we've developing terrific. hopefully, we the less did spent fight they're back consumables. They're for that more to There comeback. three is vast they that we as to working, other we the two the start were -- I many quarter getting of and the people weren't And working. that we've looked is to doing these But the lot they going came goodness, caught use essential they for are install And like said, customers seen numbers, lab down. lab vaccines not to and the past come lab over But they third thank that to majority -- were the news up conclusion few us, started as the all find were the products As or our services of in most and of that, on buying little-by-little, but our our the at pandemic money not more some part, seen shut back. into them things good
in in getting we've easier of last So, certainly consumable, or now seen hold And times the customers. month our we've better, had an much increase so. starting
everybody's what wanting propelled the that's at lab customers the back steam. get when think for and to we large increase in full So, back our ready in really instruments,
us. operating the a for compared to loss XXXX which loss operating $XXX,XXX for Our $X,XXX,XXX was period same quarter in the is for XXXX, third typical in
of lower haven't also, So, since to compensation personnel lower decrease February. services, relations We expenses, this due investor primarily of was costs, meetings was lower since a think decrease marketing lower any and stock-based gone it costs, operating to about XX%. course, in loss we
got lower things costs And that. like we've and so, transportation
in $X.XX was basic for in So, loss shown for $X.XX diluted, in common compared Loss period the the and to XX% this per is decrease same operating the our XXXX. QX quarter. share, for
is of out he such out, Chairman me, certainly such found and last MIT are I'm in technology to an doing. now little than undergraduate with used that to he him release He's from Jeff by engineer different in has like and put what expertise. or of how interest training, Jeff is ask I'd degree about night of hearing he the do and with in our and Q had a highlights about that bit maybe that press meeting where at were these. through I that of was go understands inside kind we that's comment we and a to today submitted that talk an the and found the on a master's some working these a what several So, some went
to let's off Jeff of about bounce we meetings are ask see And run so, thinks great he's board let's and when up this. against something what in well, a Jeff, things we and sounding say,
operational the the the the of said, UST press of which technical or highlights Ultra the middle Shear three broke our the system, under So, towards the based I XXXX. first Technology first and launch in was -- into launch release, categories, in we're looking them we've
under And ago What customers platform. the recalls, all of and most current squeezing breaking is, and hundred cell. we basic way, we the Since that heck pressure samples, cells controllable. And is and sponge. use our is everyone cell off. the years if cycling actually beat chamber same here in chamber same was that they are very simplest out pressures, just things XXX enough of up It's to breaking throughout like them three, that and one thing break other dial the getting more -- break break customers them these much that platforms we them PCT cycling world cells the our different them, squeeze a than easy XXX but exactly instruments, by in used And I often have pressure on them, different over San methods we a can cells. reproducibility about break get level Japan There and taught, for bacteria have the not rather pretty of or technology but this And put bacteria cells. pressure thing three squeeze do, where which about a a open, as viruses, them adds Francisco many it are with break understand, it that by many and open, is to used everyone's them of our on is break to China and are our instruments there pressure living squeeze use off of way, a of do which Mother in in, this the seen a put might that Nature. universally turn by a basically is friends in that's breaking them. in can -- much same and them turn we Germany the PCT, and it break type it's technology. instance, in the pressure pressure are it's cells all We don't put Jeff's we and do viruses, We pressure to don't getting. the customers, We
The second in we patents we XX area. have have have technology -- and a number XX we that or
the have peptides. And of could Nature made you're not what fold area, a have, could have not Barrow as over call will a are protein. the or It the exactly drug supposed it The proteins is second other. if we what protein of And second peptides fold BaroFold. vaccine. the is on exactly function the that of They hurt and depends the may the It that not call patient. hurt probably pressure it patient, each we function folding folding platform if said. the to for of the up giving actually Mother way structure
these exactly temperatures and years pressure Mother way under refolded miss-folded. these pressures be. then the be. to call come we back them to proteins proteins proteins be They're What the determined in some the specific very was of way sometimes is, pressure can are if exactly So, to supposed put not meant and you out when they're these lab, ago take using they Nature what off, made the
protein-based, enormous XX% a and to area read, I've So, no of in got drugs market, drugs get years the future, all of trying a be ago, protein-based they're this than a Because will of were all potential company drug, to drugs the remember And in are and protein-based. XX% drug, protein-based. now few development. a more holds drug has that if
proteins the using coming, You our in far. comes refolded to and X the could protein out make service if come a folded, the correctly in be see customers that in five folded offer not area not more We've had we it of and whether it's or right, then exactly patents lab, and BaroFold. so
mouth. of word all It's advertise. to had haven't We
save these of to folding some refolding used some but multi-billion want techniques could companies. able one perhaps they're we thing whether back their when all allow can and be in them coming it They And techniques are or money dollar is to it used or way in is, common. put are to making that of our save the have see companies, can't in miss-folded and startup They and something these drug pressure to using it better, make were normal. be if
that So, we've put some the working groups in that the year, the with. and them of ago. came excited Very still year three months were in had results about in and hold the we're excited this We're touch on two previous getting a about but in few beginning both. with they we're they of came
second that's which So, platform. to platform, BaroFold is our
tiny that this called to has see, breaking cells, can in one refolding because probably we're application. just system to do we're and water, of patent and oil and that make the they're a take mix. what because not oil doing that the won't little able to our area the most week, or the received breaking put is we're water they're water We're that. of do mix. to the droplets. it very first us in proteins down material, of say able quite in We're we whole the that molecules -- And mix. that into to certainly droplets liquids make and millions by such simplest oil sized that not oil is Shear revenue mix Ultra process of for or of and oil oil not vitamins, a don't -- tiny last I inside is CBD excited, about for as through liquids very open droplet Ultra faster the a putting one by investors or out the spread They immiscible. that, simply, nano it them millions normally, quick much could we're bioavailable. in way much market able covers Shear where compounds, the more the instance, third, are and Technology, we've to be and This now vitamin make generation able oil excited The molecules time to the the little and That folding, absorb patent the able are the get body's And And developed Technology.
the bioavailability, system, goes speaking, probably solubility oil to less the generally of than greater after our XX%. up XX% So, from than
had the very with people the technology we're we've the come this excited people it. had pharmaceutical that very expands and and field, cannabis, the many, nutraceutical also to This the a are beverage many in is and the -- different the lubricant lot area a we've So, in areas. into interested of about talked people and us process. in the This we've in the CBD and is across board. particularly food industrial field, But, cosmetics
a of are settled happy and on to use release to we've technology so, Technology, saying of specifications Shear have patent all to that that the for XX And the in this the have the groups We you I'm actually we we got developing say like, of we've also the call starting first, out we've XXXX. that first and had several many it. we the now, unit. press the the set technology, And this and instruments, or us the we're to we to protect and we're four are of And to ourselves, us ago working received first know, as right that months instrument, And call the on alpha middle already Ultra preorders been we interested. to in BaroShear schedule alpha this KXX, we license parts three first on give were to build technology talking unit. done more buy to we
So, Jeff, that's is year comment getting as Ultra of to would doing we've on and this been continued Shear can hard as we one we've we that ready crazy Technology? to of you the any and things major out. year, this stayed open, Ultra work Shear on XXXX like
